雪榕生物
(300511)
| 流通市值：22.06亿 | | | 总市值：25.85亿 |
| 流通股本：4.70亿 | | | 总股本：5.51亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,641,052,971.34 | 1,070,868,016.87 | 603,985,503.43 | 2,565,144,194.86 |
| 营业收入 | 1,641,052,971.34 | 1,070,868,016.87 | 603,985,503.43 | 2,565,144,194.86 |
| 二、营业总成本 | 1,812,691,932.39 | 1,220,359,916 | 602,081,762.76 | 2,701,947,257.02 |
| 营业成本 | 1,603,496,917.96 | 1,066,559,065.44 | 525,607,758.38 | 2,350,071,903.7 |
| 税金及附加 | 16,227,428.74 | 11,199,479.63 | 5,051,614.73 | 20,540,902.99 |
| 销售费用 | 22,120,937.77 | 15,656,983.71 | 8,269,934.73 | 80,244,018.43 |
| 管理费用 | 96,570,903.9 | 64,712,226.47 | 30,284,427.06 | 160,272,574.41 |
| 研发费用 | 2,994,275.99 | 2,251,021.28 | 1,518,369.89 | 6,838,068.27 |
| 财务费用 | 71,281,468.03 | 59,981,139.47 | 31,349,657.97 | 83,979,789.22 |
| 其中:利息费用 | 74,726,173.22 | 51,424,854.79 | 25,195,177.54 | 88,772,387.04 |
| 其中:利息收入 | 1,943,393.51 | 1,440,878.38 | 622,948.34 | 7,159,536.25 |
| 加:公允价值变动收益 | - | - | - | -3,759,090.89 |
| 加:投资收益 | - | - | - | 1,105,984.63 |
| 资产处置收益 | 8,370,860.22 | 8,187,783.49 | 6,333,798.19 | 497,888.61 |
| 资产减值损失(新) | - | - | - | -58,596,350.25 |
| 信用减值损失(新) | -624,425.34 | -408,725.3 | -94,552.57 | -3,861,290.65 |
| 其他收益 | 8,688,181.01 | 4,797,713.55 | 2,479,024.48 | 11,026,595.62 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -155,204,345.16 | -136,915,127.39 | 10,622,010.77 | -190,389,325.09 |
| 加:营业外收入 | 970,676.49 | 605,600.75 | 458,664.03 | 5,919,302.37 |
| 减:营业外支出 | 1,091,882.1 | 796,871.83 | 377,809.8 | 7,629,106.67 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -155,325,550.77 | -137,106,398.47 | 10,702,865 | -192,099,129.39 |
| 减:所得税费用 | 66.28 | 39.39 | 18.5 | 235,081 |
| 六、净利润 | -155,325,617.05 | -137,106,437.86 | 10,702,846.5 | -192,334,210.39 |
| 持续经营净利润 | -155,325,617.05 | -137,106,437.86 | 10,702,846.5 | -192,334,210.39 |
| 归属于母公司股东的净利润 | -163,809,859.67 | -143,594,085.68 | 5,240,339.19 | -188,062,576.34 |
| 少数股东损益 | 8,484,242.62 | 6,487,647.82 | 5,462,507.31 | -4,271,634.05 |
| (一)基本每股收益 | -0.33 | -0.29 | 0.01 | -0.38 |
| (二)稀释每股收益 | -0.33 | -0.29 | 0.01 | -0.38 |
| 八、其他综合收益 | 387,936.84 | 150,330.82 | 1,422,242.15 | -1,116,895.86 |
| 归属于母公司股东的其他综合收益 | 276,407.24 | 42,222 | 825,141.39 | -672,418.3 |
| 九、综合收益总额 | -154,937,680.21 | -136,956,107.04 | 12,125,088.65 | -193,451,106.25 |
| 归属于母公司股东的综合收益总额 | -163,533,452.43 | -143,551,863.68 | 6,065,480.58 | -188,734,994.64 |
| 归属于少数股东的综合收益总额 | 8,595,772.22 | 6,595,756.64 | 6,059,608.07 | -4,716,111.61 |
| 公告日期 | 2024-10-25 | 2024-08-29 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |